Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Inside Moderna's Deal With The US

Plus: Generex Forges Vaccine Partnership

Executive Summary

Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.

You may also be interested in...



Will Moderna-NIH Patent Dispute Change Government-Industry Collaborations?

US government may add provisions to future agreements to ensure its inventorship rights and make terms more favorable to the public. Lawyers say it will be difficult for Moderna to exclude NIH as co-inventor. But NIH lost a similar battle over AZT patents.

Can Moderna Meet Its COVID Vaccine Expectations?

Analysts have cut forecasts for Moderna’s COVID-19 vaccine – but there is still much to play for as key readouts approach.

Moderna Takes Middle Ground On Pricing With 100 Million Dose US Agreement

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel